One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Two leading medical stocks that appear reasonable at current levels are AbbVie ( ABBV 0.78%) and Merck ( MRK +0.31%). The former has actually beaten the market in 2025, while the latter is in the red ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Merck Foundation Chairman & Chief Executive Officer (CEO) and the First Lady of Zimbabwe Celebrate 7 Years of Long-Term ...